The stock of Elevation Oncology Inc (ELEV) has seen a -3.28% decrease in the past week, with a -30.18% drop in the past month, and a -46.62% decrease in the past quarter. The volatility ratio for the week is 8.31%, and the volatility levels for the past 30 days are at 8.28% for ELEV. The simple moving average for the past 20 days is -18.49% for ELEV’s stock, with a 12.98% simple moving average for the past 200 days.
Is It Worth Investing in Elevation Oncology Inc (NASDAQ: ELEV) Right Now?
Additionally, the 36-month beta value for ELEV is 1.35. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ELEV is 47.90M and currently, short sellers hold a 11.06% ratio of that float. The average trading volume of ELEV on June 27, 2024 was 680.00K shares.
ELEV) stock’s latest price update
Elevation Oncology Inc (NASDAQ: ELEV) has experienced a rise in its stock price by 13.80 compared to its previous closing price of 2.35. However, the company has seen a fall of -3.28% in its stock price over the last five trading days. prnewswire.com reported 2024-06-27 that — Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively — — Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 — — Combination cohorts broaden market opportunity for EO-3021 to address unmet needs across second- and first-line gastric or gastroesophageal junction cancer settings — — On-track to provide update from ongoing Phase 1 clinical trial evaluating monotherapy EO-3021 by mid-3Q 2024, with additional data in 1H 2025 — BOSTON, June 27, 2024 /PRNewswire/ — Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Following recently signed clinical supply agreements with Eli Lilly and Company (Lilly) and GSK, respectively, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab, a VEGFR2 inhibitor, in second-line patients and in combination with dostarlimab, a PD-1 inhibitor, in the front-line setting.
Analysts’ Opinion of ELEV
Many brokerage firms have already submitted their reports for ELEV stocks, with Piper Sandler repeating the rating for ELEV by listing it as a “Overweight.” The predicted price for ELEV in the upcoming period, according to Piper Sandler is $10 based on the research report published on May 31, 2024 of the current year 2024.
Stephens, on the other hand, stated in their research note that they expect to see ELEV reach a price target of $8. The rating they have provided for ELEV stocks is “Overweight” according to the report published on May 14th, 2024.
JMP Securities gave a rating of “Mkt Outperform” to ELEV, setting the target price at $7 in the report published on March 01st of the current year.
ELEV Trading at -25.16% from the 50-Day Moving Average
After a stumble in the market that brought ELEV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.13% of loss for the given period.
Volatility was left at 8.28%, however, over the last 30 days, the volatility rate increased by 8.31%, as shares sank -32.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -39.18% lower at present.
During the last 5 trading sessions, ELEV fell by -3.44%, which changed the moving average for the period of 200-days by +289.78% in comparison to the 20-day moving average, which settled at $3.22. In addition, Elevation Oncology Inc saw 397.99% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ELEV
Current profitability levels for the company are sitting at:
- -664.98 for the present operating margin
- 0.33 for the gross margin
The net margin for Elevation Oncology Inc stands at -678.48. The total capital return value is set at -0.36. Equity return is now at value -71.82, with -42.35 for asset returns.
Based on Elevation Oncology Inc (ELEV), the company’s capital structure generated 0.29 points at debt to capital in total, while cash flow to debt ratio is standing at -1.59. The debt to equity ratio resting at 0.41. The interest coverage ratio of the stock is -9.01.
Currently, EBITDA for the company is -40.3 million with net debt to EBITDA at 1.55. When we switch over and look at the enterprise to sales, we see a ratio of 1493.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 46.22.
Conclusion
In conclusion, Elevation Oncology Inc (ELEV) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
